La clínica es el pilar del diagnóstico | 31 OCT 22

Endocarditis infecciosa de válvula nativa

La fiebre y el soplo cardíaco, las dos características de la endocarditis infecciosa, están presentes en casi el 90% y el 75% de los pacientes, respectivamente
Autor/a: Henry F. Chambers, Arnold S. Bayer N. Engl. J. Med. 2020;383:567-76
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

1-Cahill TJ, Prendergast BD. Infective endocarditis. Lancet 2016;387:882-93.

2. Bin Abdulhak AA, Baddour LM, Erwin PJ, et al. Global and regional burden of infective endocarditis, 1990-2010: a systematic review of the literature. Glob Heart 2014;9:131-43.

3.Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009;169:463-73.

4.Ambrosioni J, Hernandez-Meneses M, Téllez A, et al. The 1changing epidemiology of infective endocarditis in the twenty-first century. Curr Infect Dis Rep 2017;19:21.

5. Pettersson GB, Hussain ST, Shrestha NK, et al. Infective endocarditis: an atlas of disease progression for describing, staging, coding, and understanding the pathology. J Thorac Cardiovasc Surg 2014; 147(4):1142-1149.e2.

6. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30:633-8.

7. Habib G, Derumeaux G, Avierinos JF, et al. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. J Am Coll Cardiol 1999;33: 2023-9.

8. Prendergast BD. Diagnostic criteria and problems in infective endocarditis. Heart 2004;90:611-3.

9. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation 2015;132:1435-86.

10. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) — endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36:3075-128.

11. Fournier P-E, Gouriet F, Casalta J-P, et al. Blood culture-negative endocarditis: improving the diagnostic yield using new diagnostic tools. Medicine (Baltimore) 2017;96(47):e8392.

12. Liesman RM, Pritt BS, Maleszewski JJ, Patel R. Laboratory diagnosis of infective endocarditis. J Clin Microbiol 2017;55: 2599-608.

12.  Afonso L, Kottam A, Reddy V, Penumetcha A. Echocardiography in infective endocarditis: state of the art. Curr Cardiol Rep 2017;19:127.

14. Habib G, Badano L, Tribouilloy C, et al. Recommendations for the practice of echocardiography in infective endocarditis. Eur J Echocardiogr 2010;11:202-19.

15. Bai AD, Steinberg M, Showler A, et al. Diagnostic accuracy of transthoracic echocardiography for infective endocarditis findings using transesophageal echocardiography as the reference standard: a meta-analysis. J Am Soc Echocardiogr 2017;30(7):639-646.e8.

16. Gomes A, Glaudemans AWJM, Touw DJ, et al. Diagnostic value of imaging in infective endocarditis: a systematic review. Lancet Infect Dis 2017;17(1):e1-e14.

17. Wong D, Rubinshtein R, Keynan Y. Alternative cardiac imaging modalities to echocardiography for the diagnosis of infective endocarditis. Am J Cardiol 2016; 118:1410-8.

18. Cosgrove SE, Vigliani GA, Fowler VG Jr, et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009;48:713-21.

19. Thwaites GE, Scarborough M, Szubert A, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018;391: 668-78.

20. Nakatani S, Ohara T, Ashihara K, et al. JCS 2017 guideline on prevention and treatment of infective endocarditis. Circ J 2019;83:1767-809.

21.  Weis S, Kesselmeier M, Davis JS, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2019;25:818-27. 22. Nannini EC, Stryjewski ME, Singh KV, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother 2009; 53:3437-41.

23. Miller WR, Seas C, Carvajal LP, et al. The cefazolin inoculum effect is associated with increased mortality in methicillin-susceptible Staphylococcus aureus bacteremia. Open Forum Infect Dis 2018;5(6): ofy123.

24. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024